Physician profile
Troy D Schmidt
NPI 1831275429
$3,648.05
in general payments reported to CMS, 2019-2025
22 companies · $394 in 2025
The $394 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $942 · 2020: $227 · 2021: $184 · 2022: $841 · 2023: $627 · 2024: $432 · 2025: $394.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,454.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,453.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,688.49 | 2019-2025 | Rinvoq, Skyrizi, Viberzi |
| Janssen Biotech, INC. | $408.53 | 2019-2023 | Stelara, Simponi, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $334.25 | 2019-2023 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $322.14 | 2019-2025 | Entyvio |
| Daiichi Sankyo INC. | $165.86 | 2019-2023 | Injectafer |
| Celgene Corporation | $147.06 | 2023-2024 | Zeposia |
| Qol Medical, LLC | $91.85 | 2019-2022 | |
| Braintree Laboratories, INC. | $68.53 | 2019 | |
| Merck Sharp & Dohme LLC | $53.47 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $52.93 | 2019-2022 | |
| Organon LLC | $52.06 | 2023 | Renflexis |
| Intercept Pharmaceuticals, INC. | $48.57 | 2019-2022 | |
| Allergan, INC. | $44.92 | 2019 | |
| Ethicon US, LLC | $34.53 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $30.15 | 2023 | Dupixent |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $22.87 | 2023 | Rebyota |
| Lilly USA, LLC | $19.88 | 2024 | Omvoh |
| Amgen INC. | $18.38 | 2021 | |
| Nestle Healthcare Nutrition INC. | $16.59 | 2022 | |
| Redhill Biopharma INC. | $15.26 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $11.73 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$56,121.38 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Troy Schmidt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.